<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59197">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335346</url>
  </required_header>
  <id_info>
    <org_study_id>15611</org_study_id>
    <secondary_id>F1J-JE-HMHD</secondary_id>
    <nct_id>NCT02335346</nct_id>
  </id_info>
  <brief_title>An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480)</brief_title>
  <official_title>An Open Label Extension Study of Phase 3 Trial of Duloxetine in Patients With Osteoarthritis and Knee Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of duloxetine in participants
      with osteoarthritis and knee pain. The study will last for 1 year.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Drug Related Adverse Events (AEs) or any Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline through Week 53</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression-Improvement (PGI-I) at 50 Weeks</measure>
    <time_frame>Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Severity (CGI-S) at 50 Weeks</measure>
    <time_frame>Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to 50 Weeks on the Brief Pain Inventory-Severity and Interference Rating Short Form (BPI-SF)</measure>
    <time_frame>Baseline, Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to 50 Weeks on the Western Ontario and McMaster Osteoarthritis Index (WOMAC) Questionnaire Total Score</measure>
    <time_frame>Baseline, Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to 50 Weeks on the 36-Item Short-Form Health Survey (SF-36)</measure>
    <time_frame>Baseline, Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to 50 Weeks on the 5 Dimension (EQ-5D) Version of the European Quality of Life Instrument</measure>
    <time_frame>Baseline, Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to 50 Weeks on the Beck Depression Inventory (BDI-II) Total Score</measure>
    <time_frame>Baseline, Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Fall Events from Fall Questionnaire</measure>
    <time_frame>Week 50</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. During tapering period, dose of 40 mg for one week and then 20 mg for the last week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <other_name>LY248686</other_name>
    <other_name>Cymbalta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (Consecutive Participants)

          -  Participants who have completed the 15-week treatment in the preceding study HMGX.

        (New Participants)

          -  Participants with present osteoarthritis (OA) based on American College of
             Rheumatology (ACR) classification of idiopathic OA of the knee.

          -  Have pain for ≥14 days of each month for 3 months prior to study entry.

          -  Have a score of ≥4 on the BPI average pain score at the start of the study.

        (Consecutive and New Participants)

          -  Females of child-bearing potential must test negative (-) on a pregnancy test.

        Exclusion Criteria:

        (New Participants)

          -  Participants who have any previous diagnosis of psychosis, bipolar disorder, or
             schizoaffective disorder.

          -  Participants who have major depressive disorder as determined using depression module
             of the Mini-International Neuropsychiatric Interview (M.I.N.I.).

          -  Participants who have received intrarticular hyaluronate or steroids, joint lavage,
             or other invasive therapies to the knee in the past 1 week.

          -  Participants who have had knee arthroscopy of the index knee within the past year or
             joint replacement of the index knee or osteotomy at any time.

          -  Participants have a prior synovial fluid analysis showing a white blood cell (WBC)
             ≥2000 cubic millimeters (mm3) that is indicative of a diagnosis other than OA.

          -  Participants who have a history of having more than one medical allergy.

          -  Are non-ambulatory or require the use of crutches or a walker.

          -  Have frequent falls that could result in hospitalization or could compromise response
             to treatment.

          -  Have a history of drug abuse or dependence within the past year, including alcohol
             and excluding nicotine and caffeine.

          -  Have a positive urine drug screen for any substances of abuse or excluded medication.

          -  Have received administration of another investigational drug within the 30 days prior
             to enrollment.

          -  Have had previous exposure to duloxetine or completed/withdrawn from any study
             investigating duloxetine.

        (Consecutive and New Participants)

          -  Participants who have serious cardiovascular, hepatic, renal, endocrine, respiratory,
             or hematologic illness, peripheral vascular disease, or other medical condition or
             neuropsychiatric conditions or clinically significant laboratory abnormalities or
             electrocardiographic abnormalities.

          -  Participants who have alanine aminotransferase (ALT) or aspartate aminotransferase
             (AST) higher than 100 international units per liter (IU/L) or total bilirubin higher
             than 1.6 milligrams/deciliter (mg/dL).

          -  Participants having serum creatinine level higher than 2.0 mg/dL, or had renal
             transplantation or receiving renal dialysis.

          -  Participants who have a diagnosis of inflammatory arthritis (that is, rheumatoid
             arthritis) or an autoimmune disorder (excluding inactive Hashimoto's thyroiditis and
             Type 1 diabetes).

          -  Participants who have uncorrected thyroid disease, uncontrolled narrow-angle
             glaucoma, history of uncontrolled seizures, or uncontrolled or poorly controlled
             hypertension.

          -  Participants who have end stage bone disease or surgery planned during the trial for
             the index joint.

          -  Participants treated with a monoamine oxidase inhibitor (MAO) within 14 days prior to
             baseline, or those with the potential need to use MAO inhibitor during the study or
             within 5 days of discontinuation of investigational drug.

          -  Participants who answer 'yes' to any of the questions about active suicidal
             ideation/intent/behaviors occurring within the past month (Columbia-Suicide Severity
             Rating Scale, suicide ideation section-questions 4 and 5; suicidal behaviors
             section).

          -  Have a primary painful condition that may interfere with assessment of the index
             joint, i.e., knee.

          -  Pregnant participants, female participants who wish to be pregnant during the
             clinical study period, or participants who are breast-feeding; or male participants
             who wish pregnancy of the partner.

          -  Participants who cannot use appropriate contraceptive method or do not want to use
             that from the start of the study until one month after the end of administration of
             the investigational drug.

          -  Considered as inappropriate participation to the study for any medical or other
             reason by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kobe</city>
        <zip>650-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 4, 2016</lastchanged_date>
  <firstreceived_date>January 7, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
